Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 101,716 |
|
|||||
| News | - | ||||||
| Day High | 2.06 | Low High |
|||||
| Day Low | 1.95 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Erasca Inc | ERAS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0006 | 0.03% | 2.0406 | 10:29:47 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.01 | 1.95 | 2.06 | 2.04 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 686 | 101,716 | US$ 2.02 | US$ 204,974 | - | 1.51 - 3.375 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 10:31:45 | 1 | US$ 2.04 | USD |
Erasca Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 302.17M | 151.09M | - | 0 | -125.04M | -0.83 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Erasca News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ERAS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.85 | 2.065 | 1.81 | 1.93 | 456,937 | 0.1906 | 10.30% |
| 1 Month | 2.08 | 2.44 | 1.74 | 2.06 | 653,299 | -0.0394 | -1.89% |
| 3 Months | 1.70 | 2.655 | 1.66 | 2.15 | 804,422 | 0.3406 | 20.04% |
| 6 Months | 2.01 | 2.655 | 1.51 | 2.00 | 958,847 | 0.0306 | 1.52% |
| 1 Year | 2.75 | 3.375 | 1.51 | 2.24 | 798,637 | -0.7094 | -25.80% |
| 3 Years | 15.90 | 24.47 | 1.51 | 6.03 | 728,596 | -13.86 | -87.17% |
| 5 Years | 15.90 | 24.47 | 1.51 | 6.03 | 728,596 | -13.86 | -87.17% |
Erasca Description
| Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. |
